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Material and Methods: The analysis included all the patients 
treated for gliosarcoma between 1998 and 2014 in seven 
French academic centres. 
 
Results: Seventy-five patients with a median age of 60 years 
(range from 23 to 79 years) were treated with a combination 
of surgery (n=66), radiotherapy (adjuvant for 64 patients and 
exclusive for 8 patients) and temozolomide based 
chemotherapy (n=58). Median follow-up was 12 months 
(range from 2 to 71 months). Two-year overall survival (OS) 
and disease free survival rates were 12% (95% CI: 4-20%) and 
2% (95% IC: 0-6%), respectively. The median OS was 13 
months. Treatment at recurrence consisted of chemotherapy 
(n=38) (bevazicumab for 18 patients, resumed temozolomide 
for 10 patients), salvage surgery (n=8) and 
radiochemotherapy (n=1). In univariate analysis, younger 
age, high total dose of radiotherapy, long time to recurrence 
and treatment at recurrence increased significantly OS. In 
multivariate analysis, high total dose of radiotherapy (HR = 
0.97, p=0.007) and treatment at recurrence (HR=0.28 
p<0.001) were favourable prognostic factor of OS.  
 
Conclusion: High dose of radiotherapy and salvage surgery 
increase OS of gliosarcoma. 
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Purpose or Objective: JCOG0211 study demonstrated that 
the 5-year local control, 5-y OS and 5-y PFS of patients 
treated with RT-DeVIC were 94, 70 and 63%, respectively. 
NKEA project (UMIN000015491) conducted a multi-
institutional retrospective study to clarify the changing 
current practice of the treatment for Extranodal natural 
killer(NK)/T-cell lymphoma nasal type(ENKL) over the first 
decade of this century in Japan, reviewing detailed 
information on treatment, clinical features and prognosis of 
patients with ENKL. The aim of this sub-study is to 
investigate the relationship between local failure patterns 
and radiation therapy before and after JCOG0211 study. 
 
Material and Methods: Selection criteria of NKEA survey are 
newly pathologically diagnosed ENKL, any stage, and any type 
of treatment and treated from 2000 to 2013. From 32 
institutions, more than 384 data of patients with ENKL have 
been registering in the NKEA project database. Of them, 
radiation therapy (RT) data, focusing on CTV setting, of 233 
patients with localized nasal ENKL were evaluated with the 
JROSG-lymphoma committee. 
 
Results: The baseline patients characteristics were 
followings, median age was 58 years old (range 18-88), male 
dominant (2:1), stage I/II=162/66(2.4:1). The median dose of 
RT was 50 Gy (range 9-60), delivering median 25 (range 3-33) 
fractionation over 37 (range 9-106) days. The 3D-CRT (CT 
based RT planning) was applied in 88% of patients and IMRT in 
3%, using shrinking technique; 70%. RT was interrupted with 
15% of patients due to hematological and mucosal toxicities. 
After JCOG0211 study, 49% of RT was designed according to 
JCOG0211 RT protocol, while 80% or more were not 
compliant RT protocol before/during JCOG0211. The local 
control was 74% for all population, 88% of local control rate 
was observed in patients treated with RT compliant with 
JCOG0211 RT protocol (extended RT), while 70% in patients 
not compliant with JCOG RT protocol (small field/limited 
RT). Based on the results of RT-QA review; we would like 
proposed the CTV guideline for IMRT/VMAT. 
 
Conclusion: A multi-institutional retrospective survey after 
prospective clinical trial is important to review how the 
results of trial influence on the community standard practice 
of the treatment for rare lymphoma, and observance of 
radiation therapy guidance. The extended RT had higher local 
control rate than small limited RT. 
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Purpose or Objective: Primary thyroid lymphoma (PTL) is a 
relatively rare entity of extra-nodal lymphoma. There was no 
randomized clinical trial and the optimal treatment is not 
established. The purpose of this retrospective study is to 
verify the effectiveness and safety of our treatment protocol 
with long term follow-up.  
 
Material and Methods: The stage IE - IIE PTL patients treated 
with combined treatment including radiotherapy and 
followed up at least three years were eligible for this 
retrospective study. We used CHOP or CHOP-like regimens 
with or without rituximab. Chemotherapy was not 
administered to the patients who were IEA MALToma treated 
in or after 2007 or have a contraindication to it. Acute and 
late toxicities were graded by CTCAE v4.0. 
 
Results: Seventy-two PTL patients were analyzed and median 
follow-up period was 91 months (37 – 238 m) . The doses of 
radiotherapy were 36 - 61.2 Gy (median 41.4Gy). Seven-year 
overall survival and cause specific survival were 98.6 % and 
92.2 %, respectively. Recurrences were observed in 7 
patients; five of them were retreated (chemotherapy +/- 
radiotherapy) and four patients achieved complete remission. 
Three patients died during follow-up; 2 of them due to 
malignant lymphoma, one due to breast cancer. Grade 3 
dermatitis, mucositis and pneumonitis were observed in 11 
patients (15.2 %), 4 patients (5.5 %) and 3 patients (4.2 %), 
respectively. Two patients experienced grade 3 late toxicities 
(dyspnea and laryngeal edema), but we judged they were 
less relevant to the treatment. Laryngeal carcinomas which 
located in field of radiotherapy were appeared in two 
patients. 
 
Conclusion: Effectiveness and safety of our treatment 
protocol were excellent. Because PTL patients are expected 
to have long term survival, we should optimize our treatment 
strategy to minimize acute and late toxicities and patients’ 
quality of life. 
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Purpose or Objective: The majority of patients with 
follicular lymphoma (FL) present with advanced disease and 
are considered incurable. For patients with localised stage I 
or contiguous stage II, radiotherapy (RT) may be curative, but 
a significant proportion will relapse, usually at distant sites. 
Historical series report progression free survival (PFS) rates 
at 5 & 10 years post RT of 50-60% and 40-50% respectively.  
PET-CT using Fluorodeoxyglucose (FDG) is superior to CT for 
staging of FL, with upstaging reported in 10-60% of patients. 
PET-CT has recently been recommended as the standard 
imaging modality for staging of FL.  
By measuring outcomes in patients who underwent radical RT 
for stage I/II FL staged by PET-CT, this study aims to test the 
hypothesis that more accurate staging improves selection for 
localised RT and consequent patient outcome.  
 
Material and Methods: A retrospective review was 
undertaken of all patients who underwent radical RT for 
stage I and II FL (grade 1, 2, 3a) at our institution from 2006-
2014 staged by PET-CT. Patients were newly diagnosed and 
had not received any prior systemic or radiation therapy. 
Sex, age, PET-CT stage, LDH level, FLIPI score were recorded 
and whether a bone marrow trephine (BMT) was performed. 
RT site and dose were documented. Outcomes included 
relapse within the radiation field, distant relapse and PFS.  
 
Results: Between July 2006 and November 2014, twenty-
seven patients received radical involved field RT for stage I 
or contiguous stage II FL. 11 were male and 16 female. 
Median age (range) at RT was 59 years (32-84). 11 patients 
had grade 1 FL, 5 grade 1-2, 7 grade 2 and 5 grade 3a. 23 of 
27 (85.2%) had Ann Arbor stage I disease by PET-CT. 23/27 
(85.2%) had a BMT prior to treatment. In 3 cases BMT was not 
performed and in 1 the sample was inadequate. FLIPI score 
was 0-1 in all cases. The radiation dose was 24Gy/12# or 
30.6Gy/17#, with the majority receiving 30.6Gy (23/27, 
85.2%).  
With a median follow up of 59.6 months (10.6-104), 23/27 
(85.2 %) remain free of relapse either within or outside the 
radiation field. There have been no in-field recurrences. 4 
patients (14.8%) have relapsed at distant nodal sites. The 4 
relapses occurred at 3, 3, 9 and 25 months post treatment. 5 
year PFS estimate was 84.75% (95% CI 71.01- 98.59) (see 
figure 1). For patients with stage 1 by PET-CT, 5 year PFS 
estimate was 90.87% (95% CI 68.2-97.9) and for those with 
stage 2, 50% (95% CI 6.6-.84.2). All patients were alive at 
completion of the study.  
 
Conclusion: PFS after local RT for stage I/II FL staged by 
PET-CT appears to be better than for those historically 
staged by CT. Longer follow up and more patients are needed 
to confirm our findings, but this study suggests that earlier 
series from the pre-PET-CT era may have underestimated the 
efficacy of RT as a curative treatment for truly localised FL. 
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Purpose or Objective: In 2015 the International Lymphoma 
Radiation Oncology Group (ILROG) has published guidelines 
on field and dose for modern radiotherapy in extranodal 
lymphomas. Involved site radiation therapy (ISRT) is 
recommended, and for most cases, ISRT results in smaller 
radiation fields than the involved-field radiation (IFRT) used 
previously. We analyzed our treatment plans to determine 
the compliance to ILROG guidelines in extranodal lymphomas. 
 
Material and Methods: This retrospective study is based on 
the medical records of 62 patients with extranodal 
lymphoma, who were treated with definitive radiotherapy at 
our institute between 2011 and 2014. The patients 
characteristics are shown in Table 1. After evaluating the 
compliance to ILROG guidelines for each RT plan, Fisher’s 
exact test was performed to determine factors associated 
with non-standard treatment including tumor site, histology, 
and radiation technique (IMRT vs. conventional technique). 
We calculated the progression free survival (PFS) by site and 
histology, and compared our findings to reference data 




Results: Forty-four (71%) patients were treated according to 
ILROG guidelines, and eighteen did not receive a standard 
teratment, either due to non standard treatment volume 
(n=13) or due to radiation dose (n=5).The major deviations 
from ILROG guidelines were observed in patients affected by 
pharynx lymphoma and orbital lymphoma. All patients with 
pharynx lymphoma underwent whole-Waldeyer ring RT 
instead of ISRT, while all patients with orbital lymphoma 
underwent partial-orbital RT instead of recommended whole-
orbital RT. The majority (61%) of patients managed with 
nonstandard treatment were treated with IMRT technique. 
PFS by site and histology were similar to those reported in 
the IELSG trials. 
 
Conclusion: This plans review process resulted in a high 
compliance to ILROG guidelines (71%). We identified a subset 
of patients which did not receive a standard treatment, 
therefore we are revising our treatment policy for pharynx 
lymphoma and orbital lymphoma. 
 
 
 
 
